Watchlist Price Alert

Structure Therapeutics In... (GPCR)

NASDAQ: GPCR · Real-Time Price · USD

21.73

0.11 (0.51%)

At close: Jun 20, 2025, 10:17 AM

0.51% (1D)

Bid	21.72
Market Cap	1.25B
Revenue (ttm)	n/a
Net Income (ttm)	-143.32M
EPS (ttm)	-2.58
PE Ratio (ttm)	-8.42
Forward PE	-14.51
Analyst	Buy

Ask	21.82
Volume	69,368
Avg. Volume (20D)	969,677
Open	22.00
Previous Close	21.62
Day's Range	21.23 - 22.33
52-Week Range	13.22 - 47.48
Beta	-1.97

About GPCR

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol GPCR

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for GPCR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

9 months ago

+1.03%

Structure Therapeutics shares are trading higher a... Unlock content with Pro Subscription

11 months ago

-1.15%

Shares of weight loss stocks are trading lower, possibly on continued weakness following recent weight loss data from Roche, which could cause competition concerns for companies in the space.

News

2 months ago · zacks.com

NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback

Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.

2 months ago · benzinga.com

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

Viking Therapeutics, Inc. VKTX, Eli Lilly And Co LLY and Novo Nordisk A/S NVO stocks are trading higher on Monday.

2 months ago · youtube.com

Structure Therapeutics CEO on latest GLP-1 developments

Ray Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk advancements in weight loss drugs and the development of a GLP-1 pill.

3 months ago · seekingalpha.com

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, al...